Cancers 2011, 3(4), 4010-4023; doi:10.3390/cancers3044010
Review

Role of Radiation Therapy in the Management of Renal Cell Cancer

1 Department of Radiation Oncology, The Methodist Hospital, The Methodist Hospital Research Institute, Houston, TX 77030, USA 2 Department of Radiation Oncology, The Methodist Hospital, Houston TX 77030, USA 3 Division of Oncology, University of Texas Health Science Center at Houston, Memorial Hermann Cancer Center, Houston, TX 77030, USA
* Author to whom correspondence should be addressed.
Received: 8 August 2011; in revised form: 11 October 2011 / Accepted: 19 October 2011 / Published: 26 October 2011
(This article belongs to the Special Issue Radiation and Cancers)
PDF Full-text Download PDF Full-Text [100 KB, uploaded 26 October 2011 14:11 CEST]
Abstract: Renal cell carcinoma (RCC) is traditionally considered to be radioresistant; therefore, conventional radiotherapy (RT) fraction sizes of 1.8 to 2 Gy are thought to have little role in the management of primary RCC, especially for curative disease. In the setting of metastatic RCC, conventionally fractionated RT has been an effective palliative treatment in 50% of patients. Recent technological advances in radiation oncology have led to the clinical implementation of image-guided radiotherapy, allowing biologically potent doses to the tumors intra- and extra-cranially. As predicted by radiobiologic modeling, favorable outcomes have been observed with highly hypofractionated schemes modeled after the experience with intracranial stereotactic radiosurgery (SRS) for RCC brain metastases with reported local control rates averaging 85%. At present, both primary and metastatic RCC tumors may be successfully treated using stereotactic approaches, which utilize steep dose gradients to maximally preserve function and avoid toxicity of adjacent organs including liver, uninvolved kidney, bowel, and spinal cord regions. Future endeavors will combine stereotactic body radiation therapy (SBRT) with novel targeted therapies, such as tyrosine kinase inhibitors and targeted rapamycin (mTOR) inhibitors, to maximize both local and systemic control.
Keywords: radiation therapy; stereotactic radiosurgery; renal cell carcinoma

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Blanco, A.I.; Teh, B.S.; Amato, R.J. Role of Radiation Therapy in the Management of Renal Cell Cancer. Cancers 2011, 3, 4010-4023.

AMA Style

Blanco AI, Teh BS, Amato RJ. Role of Radiation Therapy in the Management of Renal Cell Cancer. Cancers. 2011; 3(4):4010-4023.

Chicago/Turabian Style

Blanco, Angel I.; Teh, Bin S.; Amato, Robert J. 2011. "Role of Radiation Therapy in the Management of Renal Cell Cancer." Cancers 3, no. 4: 4010-4023.

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert